Thursday, 18 July 2019

WuXi's Suzhou facility clears FDA inspection

23 June 2014 | News | By BioSpectrum Bureau

The company said that this is the first FDA GLP inspection in the facility's five years of operation

The company said that this is the first FDA GLP inspection in the facility's five years of operation

Singapore: China's research and development service firm, WuXi PharmaTech has cleared the surveillance Good Laboratory Practice (GLP) inspection by US Food and Drug Administration (FDA) for its toxicology facility in Suzhou.

The company mentions this to be the first FDA GLP inspection in facility's five years of operation and the inspection lasted for five days.

WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.

"The outcome of the FDA inspection further demonstrates the consistency of our GLP compliance and quality services following the excellent results of earlier OECD and CFDA inspections," said Dr Ge Li, Chairman and CEO of WuXi PharmaTech.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls